MX2020001323A - Metodos para tratar alteraciones del comportamiento. - Google Patents

Metodos para tratar alteraciones del comportamiento.

Info

Publication number
MX2020001323A
MX2020001323A MX2020001323A MX2020001323A MX2020001323A MX 2020001323 A MX2020001323 A MX 2020001323A MX 2020001323 A MX2020001323 A MX 2020001323A MX 2020001323 A MX2020001323 A MX 2020001323A MX 2020001323 A MX2020001323 A MX 2020001323A
Authority
MX
Mexico
Prior art keywords
methods
behavior alterations
treat
treat behavior
alterations
Prior art date
Application number
MX2020001323A
Other languages
English (en)
Spanish (es)
Inventor
ROTLLANT POZO David
Maes Tamara
GRIÑÁN FERRE Christian
Pallàs Lliberia Mercè
Nadal Alemany Roser
Armario García Antonio
Original Assignee
Oryzon Genomics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics Sa filed Critical Oryzon Genomics Sa
Publication of MX2020001323A publication Critical patent/MX2020001323A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
MX2020001323A 2017-08-03 2018-08-03 Metodos para tratar alteraciones del comportamiento. MX2020001323A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17382545 2017-08-03
EP17382544 2017-08-03
EP18382299 2018-04-30
PCT/EP2018/071120 WO2019025588A1 (en) 2017-08-03 2018-08-03 METHODS OF TREATING ALTERATIONS IN BEHAVIOR

Publications (1)

Publication Number Publication Date
MX2020001323A true MX2020001323A (es) 2020-03-20

Family

ID=63077881

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020001323A MX2020001323A (es) 2017-08-03 2018-08-03 Metodos para tratar alteraciones del comportamiento.
MX2023009388A MX2023009388A (es) 2017-08-03 2020-01-31 Metodos para tratar alteraciones del comportamiento.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023009388A MX2023009388A (es) 2017-08-03 2020-01-31 Metodos para tratar alteraciones del comportamiento.

Country Status (22)

Country Link
US (2) US20200323828A1 (enExample)
EP (2) EP4512473B1 (enExample)
JP (2) JP2020529995A (enExample)
KR (3) KR102685898B1 (enExample)
CN (1) CN110996949A (enExample)
AU (2) AU2018309372B2 (enExample)
BR (1) BR112020000827A2 (enExample)
DK (2) DK3661510T3 (enExample)
ES (1) ES3001085T3 (enExample)
FI (2) FI4512473T3 (enExample)
HR (1) HRP20241716T1 (enExample)
HU (1) HUE069697T2 (enExample)
IL (1) IL272092B2 (enExample)
LT (1) LT3661510T (enExample)
MX (2) MX2020001323A (enExample)
MY (1) MY204406A (enExample)
PH (1) PH12020500211A1 (enExample)
PL (1) PL3661510T3 (enExample)
RS (1) RS66336B1 (enExample)
SG (1) SG11202000077RA (enExample)
SI (1) SI3661510T1 (enExample)
WO (1) WO2019025588A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913290QA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
AU2018309372B2 (en) * 2017-08-03 2024-08-15 Oryzon Genomics, S.A. Methods of treating behavior alterations
HRP20251471T1 (hr) * 2019-03-20 2026-01-02 Oryzon Genomics, S.A. Postupci liječenja poremećaja hiperaktivnosti s deficitom pažnje korištenjem inhibitora kdm1a kao što je spoj vafidemstat
SI3941466T1 (sl) * 2019-03-20 2026-04-30 Oryzon Genomics, S.A. Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje
EP4509176A3 (en) * 2019-09-03 2025-05-07 Oryzon Genomics, S.A. Vafidemstat for use in treating autism spectrum disorder
CN114502561B (zh) * 2019-09-29 2023-12-26 南昌弘益药业有限公司 Lsd1抑制剂
CN118604352B (zh) * 2024-05-22 2025-08-01 暨南大学 Vps13a表达促进剂在制备用于抑郁症诊断和治疗药物中的应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP1940773B1 (en) 2005-08-10 2015-03-18 Johns Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
EP2142287A4 (en) 2007-04-13 2012-05-23 Univ Johns Hopkins INHIBITORS OF LYSINPECIFIC DEMETHYLASE
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
JPWO2010143582A1 (ja) 2009-06-11 2012-11-22 公立大学法人名古屋市立大学 フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤
AU2010284221B2 (en) 2009-08-18 2016-09-22 Casero, Robert A (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2011035941A1 (en) 2009-09-25 2011-03-31 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
RS55348B1 (sr) 2010-04-19 2017-03-31 Oryzon Gnomics S A Inhibitori lizin specifične demetilaze-1 i njihova upotreba
US8765820B2 (en) 2010-04-20 2014-07-01 Universita Degli Studi Di Roma “La Sapienza” Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2
DK2598482T3 (en) * 2010-07-29 2018-06-14 Oryzon Genomics Sa ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012034116A2 (en) 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012071469A2 (en) 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
MX347913B (es) 2011-03-25 2017-05-17 Glaxosmithkline Intellectual Property (No 2) Ltd Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina.
BR112014002939A2 (pt) 2011-08-09 2017-03-01 Takeda Pharmaceuticals Co composto, medicamento, método para profilaxia ou tratamento de doença, a doença sendo esquizofrenia, alzheimer, parkinson ou huntington, uso do composto, e, método para inibir o lsd1
AU2012296639B2 (en) 2011-08-15 2016-06-09 University Of Utah Research Foundation Substituted (E)-N'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
US9289415B2 (en) 2011-09-01 2016-03-22 The Brigham And Women's Hospital, Inc. Treatment of cancer
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
AU2012324803B9 (en) 2011-10-20 2017-08-24 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
EP2907802B1 (en) 2012-10-12 2019-08-07 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
WO2014084298A1 (ja) 2012-11-28 2014-06-05 京都府公立大学法人 リシン構造を有するｌｓｄ1選択的阻害薬
US9144555B2 (en) 2012-11-30 2015-09-29 Darlene E. McCord Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition
EP2740474A1 (en) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN103054869A (zh) 2013-01-18 2013-04-24 郑州大学 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用
WO2014164867A1 (en) 2013-03-11 2014-10-09 Imago Biosciences Kdm1a inhibitors for the treatment of disease
CN105555784B (zh) 2013-06-19 2019-03-15 犹他大学研究基金会 作为组蛋白去甲基化酶抑制剂的被取代的(e)-n’-(1-苯亚乙基)苯甲酰肼类似物
CN103319466B (zh) 2013-07-04 2016-03-16 郑州大学 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用
JP6521967B2 (ja) 2013-08-06 2019-05-29 イマーゴ バイオサイエンシーズ インコーポレイテッド 疾患の治療のためのｋｄｍ１ａ阻害剤
US9186391B2 (en) 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
WO2015031564A2 (en) 2013-08-30 2015-03-05 University Of Utah Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors
CA3161836A1 (en) 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
WO2015120281A1 (en) 2014-02-07 2015-08-13 Musc Foundation For Research Development Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
JP2017508798A (ja) 2014-03-07 2017-03-30 ザ ジョンズ ホプキンス ユニバーシティ ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤
CN103893163B (zh) 2014-03-28 2016-02-03 中国药科大学 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用
NZ725262A (en) 2014-04-11 2023-01-27 Takeda Pharmaceuticals Co Cyclopropanamine compound and use thereof
CN103961340B (zh) 2014-04-30 2019-06-25 南通中国科学院海洋研究所海洋科学与技术研究发展中心 一类lsd1抑制剂及其应用
WO2015168466A1 (en) 2014-05-01 2015-11-05 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
MX375102B (es) 2014-05-30 2025-03-06 Ieo St Europeo Di Oncologia S R L Compuestos de ciclopropilamina como inhibidores de histona demetilasa
CN104119280B (zh) 2014-06-27 2016-03-16 郑州大学 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用
PL3160956T3 (pl) 2014-06-27 2020-11-30 Celgene Quanticel Research, Inc. Inhibitory demetylazy-1 specyficznej dla lizyny
WO2016003917A1 (en) 2014-07-03 2016-01-07 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
EA201790082A1 (ru) 2014-07-03 2017-08-31 Селджен Квонтисел Рисёрч, Инк. Ингибиторы лизин-специфической демитилазы-1
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
EP2993175A1 (en) 2014-09-05 2016-03-09 IEO - Istituto Europeo di Oncologia Srl Thienopyrroles as histone demethylase inhibitors
ES2935114T3 (es) 2014-09-05 2023-03-01 Celgene Quanticel Res Inc Inhibidores de la desmetilasa 1 específica de lisina
EP3250552B1 (en) 2015-01-30 2019-03-27 Genentech, Inc. Therapeutic compounds and uses thereof
JP6727216B2 (ja) 2015-02-12 2020-07-22 イマーゴ バイオサイエンシーズ インコーポレイテッド 疾患の治療のためのｋｄｍ１ａ阻害剤
CN106146361A (zh) 2015-03-16 2016-11-23 四川大学 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
CN106045862B (zh) 2015-04-10 2019-04-23 上海迪诺医药科技有限公司 环丙胺类螺(杂)环化合物、其药物组合物及应用
EP3286172B1 (en) 2015-04-23 2019-06-12 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
US20170001970A1 (en) 2015-07-02 2017-01-05 University Of Utah Research Foundation Substituted benzohydrazide analogs as histone demethylase inhibitors
DK3334709T3 (da) 2015-08-12 2025-02-03 Incyte Holdings Corp Salte af en lsd1-hæmmer
WO2017079476A1 (en) 2015-11-05 2017-05-11 Mirati Therapeutics, Inc. Lsd1 inhibitors
MX373363B (es) 2015-11-05 2020-05-21 Celgene Quanticel Res Inc Composiciones que comprenden un inhibidor de demetilasa-1 específico de lisina.
FI3381896T3 (fi) 2015-11-27 2023-04-21 Taiho Pharmaceutical Co Ltd Bifenyyliyhdiste tai sen suola
WO2017109061A1 (en) 2015-12-23 2017-06-29 Ieo - Istituto Europeo Di Oncologia S.R.L. Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
KR102720551B1 (ko) 2015-12-29 2024-10-21 미라티 테라퓨틱스, 인크. Lsd1 억제제
KR20180099768A (ko) 2015-12-30 2018-09-05 노파르티스 아게 증진된 효능을 갖는 면역 이펙터 세포 요법
WO2017149463A1 (en) 2016-03-01 2017-09-08 Novartis Ag Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
CN107200706A (zh) 2016-03-16 2017-09-26 中国科学院上海药物研究所 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
US20170283397A1 (en) 2016-03-31 2017-10-05 University Of Utah Research Foundation Substituted 1-h-indol-3-yl-benzamide and 1, 1'-biphenyl analogs as histone demethylase inhibitors
AU2017263361B2 (en) 2016-05-09 2021-08-05 Jubilant Epicore LLC Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
CN107513068A (zh) 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
CN106478639B (zh) 2016-09-05 2018-09-18 郑州大学 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用
CN106432248B (zh) 2016-09-27 2018-11-27 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
WO2018081342A1 (en) 2016-10-26 2018-05-03 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
LT3532459T (lt) 2016-10-26 2023-11-10 Constellation Pharmaceuticals, Inc. Lsd1 inhibitoriai ir jų medicininis panaudojimas
CN106831489B (zh) 2017-03-23 2018-04-17 郑州大学 苯环丙胺酰腙类化合物、制备方法及其应用
CN106928235A (zh) 2017-05-03 2017-07-07 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
AU2018309372B2 (en) * 2017-08-03 2024-08-15 Oryzon Genomics, S.A. Methods of treating behavior alterations

Also Published As

Publication number Publication date
DK3661510T3 (da) 2025-01-02
PL3661510T3 (pl) 2025-04-14
IL272092B2 (en) 2026-01-01
EP3661510A1 (en) 2020-06-10
WO2019025588A1 (en) 2019-02-07
JP2020529995A (ja) 2020-10-15
ES3001085T3 (es) 2025-03-04
AU2024264660A1 (en) 2024-12-05
IL272092A (en) 2020-03-31
HUE069697T2 (hu) 2025-04-28
EP3661510B1 (en) 2024-10-09
LT3661510T (lt) 2025-01-27
DK4512473T3 (da) 2026-08-10
AU2018309372A1 (en) 2020-01-30
HRP20241716T1 (hr) 2025-02-14
US20200323828A1 (en) 2020-10-15
PH12020500211A1 (en) 2020-10-19
JP7829235B2 (ja) 2026-03-13
RU2020109167A (ru) 2021-09-03
KR102685898B1 (ko) 2024-07-19
RS66336B1 (sr) 2025-01-31
BR112020000827A2 (pt) 2020-07-21
FI3661510T3 (fi) 2024-12-18
RU2020109167A3 (enExample) 2022-02-10
MX2023009388A (es) 2023-08-23
IL272092B1 (en) 2025-09-01
KR102912513B1 (ko) 2026-01-15
KR20200036920A (ko) 2020-04-07
SI3661510T1 (sl) 2025-03-31
US20240277673A1 (en) 2024-08-22
KR20240122847A (ko) 2024-08-13
CN110996949A (zh) 2020-04-10
KR20260015998A (ko) 2026-02-03
MY204406A (en) 2024-08-27
EP4512473A3 (en) 2025-05-14
FI4512473T3 (fi) 2026-08-06
AU2018309372B2 (en) 2024-08-15
SG11202000077RA (en) 2020-02-27
JP2023159354A (ja) 2023-10-31
EP4512473A2 (en) 2025-02-26
CA3071804A1 (en) 2019-02-07
EP4512473B1 (en) 2026-06-24

Similar Documents

Publication Publication Date Title
MX384205B (es) Metodos para usar agonistas de fxr.
PH12020500211A1 (en) Methods of treating behavior alterations
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA202092442A3 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
EA201790317A1 (ru) Ингибиторы smyd
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
EA201890262A1 (ru) Гербицидная композиция, которая содержит цинметилин и специфические ингибиторы фитоендесатуразы
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201991503A1 (ru) Производные пиразола в качестве ингибиторов malt1
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201691794A1 (ru) Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
MD20160099A2 (ro) Inhibitori ai diacilglicerol aciltransferazei 2 pentru utilizare în tratamentul tulburărilor metabolice şi a celor asociate
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2017006048A (es) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetrahidropiridi nas en calidad de inhibidores de bace1 para tratar enfermedad de alzheimer.
BR112018075310A2 (pt) metódo de tratamento de esclerose múltipla empregando um inibidor de lsd1
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы